Bioasis Technologies Inc. V.BTI

A Q on The A Forum

[JDavenport]

There was a question asked on the "A" forum, the forum that if I mention here might be frowned upon by the owners of this forum.

You might be interested in my answer.

[MineDigger]

I'd be interested to know why xB3-001 is so expensive to manufacture, as in I thought the whole point of the 2010/2011ish 12-amino acid Transcend (now xB3) was that it binned the complexity of "parent" melanotransferrin p97, and thus made it much much easier to make the conjugates. And come to that, anyone know how much it cost to make the first Herceptin conjugate (BT2111?) as used

[narmac]

,,Great question MD,,,as our tech is injection based the cost and complexity has never been discussed here that I remember. The last time I spoke with DrDR she noted that they are hands on with input on all conjugates produced. I also think that WuXi reworked our conjugate if not mistaken when they were set in manufacturing mode, something which Bioasis missed. Thats from memory,,,,its no doubt a

[JDavenport]

MineDigger asked, "I'd be interested to know why xB3-001 is so expensive to manufacture...," etc.   BT2111 is/was a chemical conjugate. It's made, essentially, by mixing trastuzumab, p97 and linkers in a container, under controlled conditions and harvesting the results. The various parts combine by covalent bonding (electron rings of the ingredients sharing electrons

[MineDigger]

Many thanks jd, let's look forward to cheaper methods. . Any chance you could enumerate the rest of the xB3 family and briefly describe what "style" of manufacture has so far been addressed (at least what has likely been done by Bioasis or our even less informative partners given the work done with them so far). Or is it just a case that they are all at the "chemial conjugate

[JDavenport]

To my knowledge, MineDigger, Bioasis has not discussed the drug structure and manufacturing details of the xB3-004 (xB3-IL-1Ra) construct used in the multiple sclerosis study that was the subject of a recent press release. In my opinion, there was a mistake in that press release. Concerning the MedImmune study, Bioasis stated that "a recombinant fusion protein of Bioasis’ proprietary

[prophetoffacts]

This post has been removed in accordance with Community Policy

[MineDigger]

jd, thanks again for these detailed answers.